R&D channel feed – Endpoints News

R&D channel feed

FDA hands down RTF letter to rare disease biotech's lead candidate

3 years ago

GSK revises Covid deal with Vir, pulls out of next-gen work

3 years ago

John Reed lands in the top R&D post at J&J in his latest Big Pharma debut

3 years ago

Incyte says under-the-radar JAK inhibitor clears a high bar for skin disorder

3 years ago

Giving first glimpse of data, Scancell looks for Covid-19 vaccine partner

3 years ago

Frequency Therapeutics reports trial fail and lays off over half of staff — stock capsizes

3 years ago

G1 Therapeutics abandons PhIII colorectal cancer trial after disappointing overall response rates

3 years ago

Bristol Myers, 2seventy roll out full Abecma data in earlier-stage cancer

3 years ago

Aristea shutters, ending hopes of a Pfizer buyout

3 years ago

Eliem CEO exits as neuro upstart chops headcount, pivots to preclinical program

3 years ago

Oramed to review strategic alternatives, clouding path forward for oral insulin

3 years ago

FDA advisors vote 8-5 in favor of GSK's Jemperli trial plan for rare rectal cancer

3 years ago

SK Bioscience plans $261M expansion in South Korea with new facility

3 years ago

Updated: AbbVie leaves some oncology programs out of 2023 pipeline highlights

3 years ago

UK microcap faces partial clinical hold in mid-stage IPF trial

3 years ago

AstraZeneca snips IL-12 candidate from pipeline as it sharpens I/O focus

3 years ago

Aligos cuts another 10% of its workforce in reprioritization for NASH and Covid pipelines

3 years ago

PhIII implosion forces Galapagos to scrap a filing plan for filgotinib

3 years ago

Ovid brings two Big Pharma vets on board as new CMO, head of epilepsy research

3 years ago

FDA assembles adcomm to review GSK's Jemperli trial plans in rectal cancer

3 years ago

Australian biotech touts a positive mid-stage data readout — with old Shire drug

3 years ago

A technicality could keep RSV shots from kids in need

3 years ago

Roche says its C5 inhibitor aced PhIII head-to-head trials with AstraZeneca’s Soliris

3 years ago

A longtime tracker on pharma R&D productivity takes a post-pandemic plunge back to a bleak reality

3 years ago

First page Previous page 97 98 99100101 102 103 Next page Last page